FDA pauses Regenxbio gene therapy trial again due to safety concerns

Food and Drug Administration (FDA) has issued a clinical hold on a gene therapy trial conducted by Regenxbio. This specific therapy is intended to treat Hunter Syndrome. According to coverage from STAT, this represents a repeated action by the regulatory body, as the FDA has paused the trial again. The hold comes at a critical juncture for the company, specifically impacting a planned refiling process. The pause was triggered by safety concerns, which Fierce Biotech specifies are linked to findings discovered via spine MRI scans. Reporting from multiple outlets highlights the immediate fallout of this regulatory decision.

Barron's reports that the company's stock is currently tumbling, while Yahoo Finance addresses the crash of RGNX stock. Fierce Biotech emphasizes that the FDA hold has effectively derailed Regenxbio's refiling plan. The coverage from WTVB confirms the official status of the clinical hold, aligning with the broader reporting across biotech and financial news platforms regarding the suspension of the Hunter Syndrome therapy trial. To understand the significance of this event, it is necessary to note that the therapy is targeting Hunter Syndrome, a condition for which the company was seeking a path toward regulatory approval. The fact that the trial has been paused again indicates a recurring issue with safety protocols or unexpected patient outcomes. Because this hold happened during a refiling phase, it suggests that previous attempts to address regulatory concerns were either insufficient or that new safety signals, specifically those identified through spine MRIs, have emerged to complicate the process.

Looking ahead, the primary focus will be on how Regenxbio addresses the specific spine MRI findings that led to the current hold. The company's ability to resume the trial will depend on satisfying the FDA's safety requirements. Market analysts and investors are monitoring the RGNX stock performance as the company navigates the derailed refiling plan. Future updates will likely center on whether the FDA identifies additional safety concerns or if the company can provide data that clears the current clinical hold on the gene therapy.